Methadone in Neuropathic Pain
INTRODUCTION: There is an important need for inexpensive drugs that treat neuropathic pain. Early research suggests that methadone may be a good, inexpensive drug to treat neuropathic pain. Methadone is available in a low cost powder that is easily prepared for different routes of administration. This study will look at the effect and safety of methadone compared to the regular treatment of morphine for the treatment of chronic neuropathic pain.
OBJECTIVES: First the investigators want to determine if methadone is effective and safe for the treatment of neuropathic pain. Since a placebo control group would be unethical, the proposed comparator will consist of the "gold standard" conventional treatment, controlled release morphine. The investigators will compare methadone to controlled-release morphine with regard to how it affects the level of pain and extent of side effects. Next the investigators want to examine safety as well as to determine whether methadone leads to improvements in physical and emotional functioning, and participants' satisfaction with the treatment.
METHODS: A double blind, randomized trial comparing methadone and controlled release morphine is proposed. After 1-week, participants will be randomly assigned to either methadone or controlled release morphine and will gradually build to a dose at which they receive adequate pain relief without unacceptable levels of side effects. This 5-week phase will be followed by a 6-week dose phase and then a 4-week tapering off phase.
Study drug: The study drug is methadone supplied in 2.5 mg tablets. The comparator will consist of controlled release morphine in 10 mg tablets. The dose of each will range from 1-12 tablets taken every 12 hours (dose ranges methadone 5-60 mg/day, controlled release morphine 20-240 mg/day).
Setting: This is a 3-site study involving pain clinics in Halifax, Nova Scotia; London, Ontario; and Calgary, Alberta.
Chronic Neuropathic Pain
Drug: Controlled Release Morphine
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
- to determine if methadone is an effective opioid for the treatment of chronic neuropathic pain [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||December 2016|
|Estimated Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
Active Comparator: Controlled Release Morphine
Controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
Drug: Controlled Release Morphine
controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01205516
|Contact: Mary E Lynch, MDfirstname.lastname@example.org|
|Contact: Myrna Yazer, RNemail@example.com|
|Canada, Nova Scotia|
|QEII Health Science Centre Pain Management Unit||Recruiting|
|Halifax, Nova Scotia, Canada, B3H 2Y9|
|Contact: Mary Lynch, MD|
|St. Joseph's Health Care Centre, Neuropathic Pain Clinic||Recruiting|
|London, Ontario, Canada, N6A4L6|
|Contact: Dwight Moulin, MD 519-685-8661 firstname.lastname@example.org|
|Alan Edwards Pain Management Unit, McGill University Health Centre||Recruiting|
|Montreal, Quebec, Canada, H3G1A4|
|Contact: Jordi Perez, MD PhD 514-934-8222 Jordi.Perez@muhc.mcgill.ca|